Study protocol for a multicenter randomised controlled trial on the (cost)effectiveness of biopsy combined with same-session MR-guided LITT versus biopsy alone in patients with primary irresectable glioblastoma (EMITT trial)

BACKGROUND: Glioblastoma (GBM) is the most common primary, malignant brain tumour with a 5-year survival of 5%. If possible, a glioblastoma is resected and further treated with chemoradiation therapy (CRT), but resection is not feasible in about 30% of cases. Current standard of care in these cases...

Descripción completa

Detalles Bibliográficos
Autores principales: Neutel, Céline L.G., Viozzi, Ilaria, Overduin, Christiaan G., Rijpma, Anne, Grutters, Janneke P.C., Hannink, Gerjon, van Eijsden, Pieter, Robe, Pierre A., Rovers, Maroeska M., ter Laan, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463911/
https://www.ncbi.nlm.nih.gov/pubmed/37612610
http://dx.doi.org/10.1186/s12885-023-11282-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463911/
https://www.ncbi.nlm.nih.gov/pubmed/37612610
http://dx.doi.org/10.1186/s12885-023-11282-7

Ejemplares similares